PartnershipJun 3, 2026, 06:07 AM
IDEAYA Biosciences Partners Roche for Pancreatic Cancer Clinical Trial
AI Summary
IDEAYA Biosciences announced a clinical collaboration with F. Hoffmann-La Roche Ltd to evaluate IDE892, its investigational PRMT5 inhibitor, in combination with Roche's pan-RAS inhibitor RG6505. The study will focus on patients with pancreatic ductal adenocarcinoma that carry an MTAP deletion, a condition with no approved targeted treatment options. IDEAYA will sponsor the clinical trial, while Roche will supply RG6505, with both companies retaining commercial rights to their respective compounds.
Key Highlights
- IDEAYA Biosciences entered a clinical collaboration with Roche.
- To evaluate IDE892 (PRMT5 inhibitor) in combination with Roche's RG6505 (pan-RAS inhibitor).
- The study targets MTAP-deleted RAS-mutant pancreatic ductal adenocarcinoma (PDAC).
- IDEAYA will sponsor the clinical trial, and Roche will supply RG6505.
- MTAP deletion is estimated to occur in up to 40% of PDAC cases.
- Both companies retain all commercial rights to their respective compounds.
- The collaboration allows for potential evaluation of a triplet combination with IDE397.
Price Impact
More from IDYA